Cushing's Disease Clinical Trial
Official title:
Cognitive Sequels of Cushing Syndrome
Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed the frequency of somatic sequelas and persistent alteration in quality of life despite the cure of the disease. More specifically, a few studies have described persistent psychopathology, maladaptive personality and cognitive impairments in patients with a history of Cushing's disease. Among these, hippocampal memory deficits have been found in the majority of studies, a finding that is consistent with the alterations described in hippocampal neurons during chronic exposure to glucocorticoids. However, the tools currently available to assess hippocampal-dependent memory are multiple, sometimes difficult to perform by clinicians and to analyze or may lack of diagnostic sensitivity. The investigators have recently developed an original tool, the virtual radial task in 3D, which has shown to be reliable to detect subtle alterations in hippocampal-dependent memory in several human diseases. The primary aim of the study is the evaluation of persistent cognitive impairments (hippocampal memory) in patients cured of Cushing's disease for at least one year using the virtual radial task in 3D and to compare it with that obtained with classical cognitive tests.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00881283 -
Long-term Cardiovascular Risk in Cured Cushing's Patients
|
||
| Completed |
NCT02568982 -
Cushing's Disease Complications
|
||
| Completed |
NCT02697734 -
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
|
Phase 3 | |
| Completed |
NCT01374906 -
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
|
Phase 3 | |
| Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
| Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
| Recruiting |
NCT00845351 -
Preoperative Bexarotene Treatment for Cushing's Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT00889525 -
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
|
Phase 3 | |
| Completed |
NCT02060383 -
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
|
Phase 4 | |
| Recruiting |
NCT04339751 -
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
|
Phase 2 | |
| Not yet recruiting |
NCT04569591 -
Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease
|
N/A | |
| Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
| Recruiting |
NCT02484755 -
Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease
|
Phase 2 | |
| Active, not recruiting |
NCT01794793 -
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
|
Phase 4 | |
| Completed |
NCT00434148 -
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
|
Phase 3 | |
| Completed |
NCT03346954 -
Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease
|
N/A | |
| Withdrawn |
NCT01925092 -
Mifepristone in Children With Refractory Cushing's Disease
|
Phase 3 | |
| Completed |
NCT01582061 -
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
|
Phase 3 | |
| Recruiting |
NCT03708900 -
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease
|
Phase 2 | |
| Terminated |
NCT00612066 -
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
|
Phase 2 |